<DOC>
	<DOCNO>NCT02615340</DOCNO>
	<brief_summary>The purpose study determine feasibility conduct randomize control trial ( RCT ) melatonin prevention delirium critically ill adult patient . The investigator hypothesize melatonin , administer schedule nightly basis ICU admission , efficacious safe prevention delirium critically ill adult .</brief_summary>
	<brief_title>Melatonin Prevention Delirium Critically Ill Patients</brief_title>
	<detailed_description>The available evidence indicate melatonin may decrease incidence delirium non-critically ill patient population ; however , trial critically ill lack . The investigator hypothesize melatonin , administer schedule nightly basis ICU admission , efficacious safe prevention delirium critically ill adult . The null hypothesis difference delirium incidence placebo melatonin . Prior conduct adequately power multi-centre , blind randomize , placebo-controlled trial critically ill patient , need good understand melatonin pharmacokinetics ( PK ) critically ill patient . This help determine appropriate dosing , drug administration issue ( specifically protocol adherence ) , adverse drug effect , recruitment rate base inclusion exclusion criterion . The specific aim conduct phase II triple blind , placebo-controlled randomize trial compare two dos melatonin ( low dose = 0.5mg high dose = 2mg ) ass feasibility future full-scale RCT . Feasibility large trial base protocol adherence participant recruitment rate . Data PK property melatonin assess determine dose future study melatonin delirium prevention critically ill .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Critically ill patient ≥18 year age Anticipated ICU stay &gt; 48 hour Able receive enteral administration study drug ( i.e . mouth feed tube = naso oro percutaneous gastric postpyloric feed tube ) Consent participate . ICU admission &gt; 48 hour prior screen Unable assess delirium ( e.g . comatose define SAS 1 2 either 'No Response ' Score A B ICDSC , chemically paralyzed neuromuscular block drug ) Screened delirium positive prior randomization ( ICDSC score ≥4 8 ) anticipate withdrawal next 48 hour History severe cognitive neurodegenerative disease ( e.g . dementia , Parkinson 's disease ) severe structural brain injury ( e.g . traumatic brain injury , intracranial hemorrhage ) ICDSC assessment tool validate patient population Unable communicate English French ( Montréal site ) Contraindications receive enteral medication ( define absolute contraindication enteral nutrition gastrointestinal obstruction , perforation , recent upper GI surgery , enteral access ) Active seizures Pregnancy Blindness Known allergy melatonin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>delirium</keyword>
	<keyword>melatonin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>feasibility</keyword>
	<keyword>prevention</keyword>
</DOC>